A systematic review of 20 randomized controlled trials found that ozone autohemotherapy (O3-AHT) reduced pain from shingles and improved quality of life compared to standard care, with no significant safety concerns. However, evidence quality was very low to moderate due to study limitations, and the treatment remains investigational in most Western healthcare systems.
Researchers systematically reviewed 20 randomized controlled trials involving 1,519 patients to assess whether ozone autohemotherapy could help manage zoster-associated pain (ZAP), the often-severe pain that follows shingles infection. The analysis used trial sequential analysis to evaluate whether the current evidence base was sufficient to draw reliable conclusions, and applied the GRADE system to rate evidence quality.
The meta-analysis showed measurable reductions in pain across multiple metrics. Patient-reported pain scores (measured via visual analog scale or numerical rating scale) decreased significantly in the ozone group compared to controls (SMD: -1.77, 95% CI: -2.16 to -1.37). This translates to a large effect size in statistical terms. The proportion of patients experiencing meaningful pain relief was also higher in the ozone group (RR: 1.21, 95% CI: 1.09 to 1.33), meaning roughly 21% more patients achieved effective pain control with ozone treatment. Quality of life scores improved by 0.75 points on the measured scale (MD: 0.75, 95% CI: 0.45 to 1.04). These findings suggest functional benefit alongside pain reduction.
Mechanistically, the ozone-treated patients showed reduced levels of inflammatory markers. Interleukin-6 (IL-6), a key inflammatory cytokine, decreased substantially (SMD: -1.84, 95% CI: -2.60 to -1.07). This aligns with the proposed mechanism that ozone may work through anti-inflammatory and immunomodulatory pathways. Safety data showed no significant difference in adverse event rates between ozone and control groups (RR: 0.77, 95% CI: 0.46 to 1.28, p = 0.31), though the authors note that heterogeneity among studies was substantial (I2 often exceeding 50%), meaning results varied considerably across trials.
Trial sequential analysis confirmed that the cumulative sample size exceeded the threshold needed to reliably detect effects on the primary outcome (pain scores), which strengthens confidence in that particular finding. However, the GRADE assessment rated overall evidence quality as very low to moderate, primarily due to bias risks in included studies and the high heterogeneity between them. The authors explicitly state that larger, higher-quality randomized controlled trials are needed before ozone autohemotherapy can be considered an established therapy.
If you are experiencing persistent shingles pain, this meta-analysis suggests ozone autohemotherapy shows measurable benefits in research settings. However, several important caveats apply:
First, ozone autohemotherapy is not widely available or approved in most Western countries, and regulatory status varies globally. It is primarily studied and used in some European and Asian healthcare systems. You should check the legal and regulatory status in your jurisdiction.
Second, the evidence quality is acknowledged as low to moderate by the authors themselves. This means the studies included had methodological limitations that reduce certainty. Factors like inadequate blinding, inconsistent outcome reporting, and variability in treatment protocols across trials all contributed to lower confidence ratings.
Third, while the pain reduction observed in these trials is substantial, standard treatments for postherpetic neuralgia (shingles pain) include antivirals, topical agents, and medications like gabapentin or pregabalin that have stronger evidence bases and established safety profiles. These should typically be considered first-line options.
If you are exploring complementary approaches alongside conventional treatment, discuss this with your healthcare provider. They can help contextualize where ozone autohemotherapy fits within your overall pain management strategy and whether clinical trial access or referral to a center offering the treatment is appropriate.
| Detail | Value |
|---|---|
| Study Type | Systematic review and meta-analysis with trial sequential analysis |
| Databases Searched | PubMed, Cochrane Library, Web of Science, Embase, Chinese Biomedical Database, CNKI, Wanfang Database, VIP Database |
| Number of Trials | 20 randomized controlled trials |
| Total Participants | 1,519 patients |
| Condition Studied | Zoster-associated pain (postherpetic neuralgia) |
| Primary Outcome | Patient-reported pain scores (VAS/NRS) |
| Secondary Outcomes | Pain relief efficacy rate, inflammatory markers (IL-6), quality of life, adverse events |
| Journal | Frontiers in Neurology |
| Publication | 2025 |
| PubMed ID | 42318237 |
| PROSPERO Registration | CRD420251145896 |
| Evidence Quality (GRADE) | Very low to moderate |
Primary source: Efficacy and safety of ozone autohemotherapy for zoster-associated pain: a meta-analysis and trial sequential analysis. Frontiers in Neurology. 2025. PubMed: 42318237
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.